不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
肿瘤微环境与靶向治疗在慢性淋巴细胞白血病中的作用
英文原题：The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia.
查看英文原题
The Role of Tumor Microenvironment and Targeted Therapy in Chronic Lymphocytic Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
慢性淋巴细胞白血病（CLL）是成人中最常见的白血病，其特征为成熟B细胞克隆性增殖。肿瘤微环境（TME）似乎在肿瘤细胞的存活和增殖中发挥关键作用。多类新药已获批用于CLL患者管理，重塑了治疗格局，其中最重要的是布鲁顿酪氨酸激酶（BTK）抑制剂和BCL-2抑制剂。两类药物均获批作为需要治疗的CLL患者的一线疗法。BTK和BCL-2在TME信号通路中的作用十分重要。本综述旨在概述TME的主要组成，以及CLL靶向治疗的现有数据。
展开英文摘要原文
Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. It is characterized by the clonal proliferation of mature B cells. The tumor microenvironment (TME) seems to play a crucial role in the survival and proliferation of tumor cells. Multiple new classes of drugs had been approved for the management of patients with CLL, reshaping the treatment paradigm.
The most important classes are Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. Both of them are approved as a first-line treatment in patients with CLL requiring treatment. The role of BTK and BCL-2 in the signaling pathways of the TME is very important. The aim of this review is to summarize the major components of the TME and the available data regarding targeted therapies in CLL.
论文信息
- 作者
- Saleh K、Arbab A、Khalife N、Khoury R、Ibrahim R、Hachem MA、Khalil C、Bou Orm C
- 单位
- International Department, Gustave Roussy Cancer Campus, 94800 Villejuif, France.France
- 文献类型
- 综述
- 期刊
- Current issues in molecular biology2025 Aug 1
- 原文标识
- PubMed 40864758 · DOI 10.3390/cimb47080604
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →